Speak directly to the analyst to clarify any post sales queries you may have.
The artificial heart market is evolving rapidly, supported by advances in mechanical circulatory support devices that are reshaping clinical pathways in cardiovascular care.
Market Snapshot: Artificial Heart Market Size and Growth
The artificial heart market grew from USD 2.82 billion in 2024 to USD 3.14 billion in 2025. Sustained double-digit CAGR is expected to drive the market to USD 6.81 billion by 2032, signaling robust industry momentum and attracting focused investment across technologies and regions.
Scope & Segmentation of the Artificial Heart Market
This report delivers comprehensive coverage across key segments. Strategic segmentation allows decision-makers to identify where opportunities and shifts may occur in the coming years.
- Type: Total Artificial Heart, Ventricular Assist Device (Biventricular, Left Ventricular, Right Ventricular)
- Application: Bridge to Transplant, Destination Therapy
- Technology: Axial, Centrifugal, Electromagnetic, Pneumatic
- End User: Ambulatory Surgical Centers, Hospitals, Specialty Clinics
- Patient Group: Adults, Pediatrics
- Regions: Americas (North America: United States, Canada, Mexico; Latin America: Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (Europe: United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland; Middle East: United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel; Africa: South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
- Companies: Abiomed, Inc.; Abbott Laboratories; Medtronic plc; SynCardia Systems, LLC; Carmat SA; Berlin Heart GmbH; Jarvik Heart, Inc.; BiVACOR, Inc.; Sun Medical Technology R&D Co., Ltd.; ReliantHeart, Inc.
Artificial Heart Market: Key Takeaways for Senior Decision-Makers
- Mechanical circulatory support is driving new standards for cardiovascular care, moving beyond experimental solutions to mainstream, life-sustaining therapies.
- Next-generation artificial heart technologies leverage miniaturization and smart control systems, enhancing both device reliability and patient experience in advanced heart failure therapy.
- Collaborations between clinicians, biomedical engineers, and regulatory agencies are accelerating preclinical research and market adoption, reinforcing a multidisciplinary approach.
- Supply chain restructuring, particularly in response to evolving trade policies, is fueling regional production initiatives and promoting resilience against market uncertainties.
- Hospitals remain the primary setting for device implantation, but ambulatory centers and specialty clinics are capturing a growing share due to streamlined protocols and remote monitoring capabilities.
- Strategic alliances are integrating digital health platforms and predictive analytics, providing continuous device monitoring and enabling outcome-based contracting strategies.
Tariff Impact: Navigating Supply Chain Changes in the Artificial Heart Market
Recent U.S. import tariffs on specialized components have prompted manufacturers to localize critical subassembly production and automate processes. Collaborative approaches between OEMs and domestic suppliers have improved supply chain resilience and promoted regional job creation. Healthcare providers have countered rising costs by renegotiating procurement and bundling device services, leading to a more integrated care delivery ecosystem.
Artificial Heart Market: Methodology & Data Sources
This report uses mixed-methods research, integrating primary interviews with cardiothoracic surgeons, biomedical engineers, procurement leaders, and policy experts. Comprehensive review of peer-reviewed journals, regulatory filings, technical white papers, and real-world clinical registries ensures robust, actionable insights. Data are triangulated and validated across multiple sources for accuracy.
Why This Report Matters for the Artificial Heart Market
- Enables strategic planning by highlighting shifts in technology, supply chains, and adoption patterns in the artificial heart market.
- Equips senior leaders with actionable intelligence to navigate regional, technological, and regulatory challenges—supporting resilient growth strategies.
- Empowers stakeholders to benchmark against evolving business models in device sales, care pathways, and service integration.
Conclusion
Technological innovation, regional production agility, and integrated patient care are defining the artificial heart market’s next growth phase. Informed strategies outlined in this report position organizations to lead in evolving cardiovascular support. For detailed analysis, request the full report.
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates.
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
3. Executive Summary
4. Market Overview
7. Cumulative Impact of Artificial Intelligence 2025
Companies Mentioned
The companies profiled in this Artificial Heart market report include:- Abiomed, Inc.
- Abbott Laboratories
- Medtronic plc
- SynCardia Systems, LLC
- Carmat SA
- Berlin Heart GmbH
- Jarvik Heart, Inc.
- BiVACOR, Inc.
- Sun Medical Technology R&D Co., Ltd.
- ReliantHeart, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 197 |
| Published | November 2025 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value ( USD | $ 3.14 Billion |
| Forecasted Market Value ( USD | $ 6.81 Billion |
| Compound Annual Growth Rate | 11.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
